1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Viking Wins First Round In Legal Battle With Ascletis Over THRβ Agonist

Both Firms Pursuing MASH Candidates

 
• By Dexter Jie Yan

The US International Trade Commission looks set to ban the importation of Ascletis's THRβ agonist into the US for use in clinical trials due to an initial legal determination on potential infringement of trade secrets related to Viking's same-class candidate VK2809.

trade secrets
Viking lodged ITC action against Ascletis in 2022, alleging unlawful and unfair methods of competition • Source: Shutterstock

Viking Therapeutics, Inc. now looks poised to win the first round in a string of legal actions it has taken against Chinese firm Ascletis Pharma, Inc., in which the US biotech alleged infringement of trade secrets related to VK2809, a thyroid hormone receptor beta (THRβ) agonist it is developing for metabolic dysfunction-associated steatohepatitis (MASH).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.

More from Therapy Areas

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.